Celularity

03/10/2026

RELEASE: Celularity has entered into a strategic commercialization partnership for its placental-derived biomaterials portfolio, a transaction expected to generate up to $35 million in upfront and milestone payments while strengthening the company’s capital position.

Importantly, Celularity will retain exclusive manufacturing rights at its FDA-compliant facility in New Jersey, preserving long-term revenue potential while sharpening focus on advancing its longevity-focused therapeutic pipeline. This move reflects a disciplined strategy to streamline operations, reduce expenses, and concentrate resources on developing placental-derived cellular therapies targeting the fundamental drivers of aging.

Read the full press release below:
https://www.globenewswire.com/news-release/2026/03/10/3252827/0/en/Celularity-Secures-35-Million-Strategic-License-Deal-Strengthens-Capital-Position-to-Advance-Longevity-Focused-Strategy.html

02/10/2026

RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses

"The funds support disciplined capital allocation to commercial opportunities for our GMP-level stem cell and other cell therapies and regenerative medicine programs, all targeting longevity and the preservation of human performance,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer.

Read the full release here:
https://www.globenewswire.com/news-release/2026/02/10/3235309/0/en/Celularity-Receives-12-2-Million-from-Sale-of-New-Jersey-Net-Operating-Losses.html

12/26/2025

RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.

Biovance® has been supported by a highly efficient, proven scalable manufacturing process since its commercial launch in April 2014, which today allows us to operate comfortably under the new Medicare reimbursement for skin substitute products.

Read the full release here:
https://www.globenewswire.com/news-release/2025/12/26/3210532/0/en/Celularity-CEO-Comments-on-Centers-for-Medicare-Medicaid-Services-Withdrawal-of-Skin-Substitute-Local-Coverage-Determinations.html

12/22/2025

RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

This closing strengthens Celularity’s financial position and provides meaningful flexibility as we continue to analyze and prioritize our platform and pipeline.

Read the full release here:

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company...

12/18/2025

RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

READ THE FULL RELEASE HERE:
https://www.globenewswire.com/news-release/2025/12/18/3208116/0/en/Celularity-Reaches-Binding-Term-Sheets-on-Financing-Transactions-to-Support-Its-Strategic-Vision.html

10/30/2025

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. This strategy fits into our objective of accessing new markets for our portfolio of commercial products.

Read the full release here:
https://www.globenewswire.com/news-release/2025/10/30/3177365/0/en/Celularity-and-DefEYE-Inc-Partner-to-Advance-Growth-of-Regenerative-Therapies-in-Eye-Care.html

10/14/2025

Exciting news! Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.

This is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options.

Read the full release here:

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with...

09/03/2025

We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest.

Read the full release here:

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord...

07/09/2025

RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

We applaud Florida’s proactive, data-driven approach to advancing investigational stem cell therapies and improving patient outcomes, for which Fountain Life, a leading science-backed longevity center, powered by AI, is an ideal partner.

Celularity’s ability today to supply clinical-grade, ethically-sourced stem cells ensures ‘Day One’ readiness under the new Florida law to partners like Fountain Life.

Fountain Life

Read the release here:
https://www.globenewswire.com/news-release/2025/07/09/3112554/0/en/Celularity-Fountain-Life-Announce-Partnership-to-Deliver-Stem-Cell-Therapies-Under-New-Florida-Law.html

07/01/2025

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

As a long-standing leader in the field of ethically sourced stem cell therapies, we applaud Florida’s intention to advance medical treatments and improve patient outcomes with this balanced approach to fostering medical innovation while upholding ethical standards.

Celularity is positioned right now to supply the stem cells necessary to fulfill the objectives of the new Florida law and we look forward to working with Florida physicians to ensure their patients have access to stem cell therapies.

Read the full release here:
https://www.globenewswire.com/news-release/2025/07/01/3108312/0/en/Celularity-Hails-New-Florida-Law-Opening-Patient-Access-to-Stem-Cell-Therapies.html

06/02/2025

Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. This also supports broader applications of this biomaterial technology beyond ophthalmology.

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface...

04/14/2025

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers.

Read the full release here:
https://www.globenewswire.com/news-release/2025/04/14/3060835/0/en/Celularity-Welcomes-CMS-Action-on-Medicare-Local-Coverage-Determination-for-Skin-Substitutes-Products.html